Stocks · News reference
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanismsDNTH312 demonstrated
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.
Read original at benzingaHC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.
Read original at benzingaWedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.
Read original at benzingaDianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.88) by 2.27 percent. This is a 2.27 percent decrease over losses of $(0.88) per share
Read original at benzinga